ReviewAmerican journal of physiology. Gastrointestinal and liver physiology2013
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome.
Review in American journal of physiology. Gastrointestinal and liver physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 6 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Pooled it
- Risk factors for developing irritable bowel syndrome: systematic umbrella review of reviews.BMC medicine · 2025Pooled it
- Pooled it
- Pharmacological treatments for patients with irritable bowel syndrome: An umbrella review of systematic reviews and meta-analyses.Medicine · 2019Pooled it
- Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.World journal of gastroenterology · 2015Pooled it
- Pooled it
- Efficacy of diet restriction with or without probiotic for treatment of patients with IBS-D: Phase I-II clinical trial.Immunity, inflammation and disease · 2023Trial
- The Effects on Immune Function and Digestive Health of Consuming the Skin and Flesh of ZespriNutrients · 2020Trial
- Psychobiotics Regulate the Anxiety Symptoms in Carriers of Allele A of IL-1Mediators of inflammation · 2020Trial
- Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults.Scientific reports · 2019Trial
- Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating.The American journal of gastroenterology · 2017Trial
- Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study.Alimentary pharmacology & therapeutics · 2014Trial
- Long-Term Risk of Parkinson's Disease Following Irritable Bowel Syndrome: A Nationwide Population-Based Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Polysaccharides fromNutrients · 2025Review
- Mapping Research Trends on Intestinal Permeability in Irritable Bowel Syndrome with a Focus on Nutrition: A Bibliometric Analysis.Nutrients · 2025Review
- Small intestinal bacterial overgrowth and intestinal methanogen overgrowth in gastrointestinal malignancies.Contemporary oncology (Poznan, Poland) · 2025Review
- Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships.Gut microbes · 2023Review
- Effects of Prometryn Exposure on Hepatopancreas Oxidative Stress and Intestinal Flora inAntioxidants (Basel, Switzerland) · 2023Article
- The immunomodulatory mechanisms for acupuncture practice.Frontiers in immunology · 2023Review
- Preventing Bacterial Translocation in Patients with Leaky Gut Syndrome: Nutrition and Pharmacological Treatment Options.International journal of molecular sciences · 2022Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The pathophysiology of irritable bowel syndrome (IBS) is believed to involve alterations in the brain-gut axis; however, the etiological triggers and mechanisms by which these changes lead to symptoms of IBS remain poorly understood. Although IBS is often considered a condition without an identified "organic" etiology, emerging evidence suggests that alterations in the gastrointestinal microbiota and altered immune function may play a role in the pathogenesis of the disorder. These recent data suggest a plausible model in which changes in the intestinal microbiota and activation of the enteric immune system may impinge upon the brain-gut axis, causing the alterations in gastrointestinal function and the clinical symptoms observed in patients with IBS. This review summarizes the current evidence for altered intestinal microbiota and immune function in IBS. It discusses the potential etiological role of these factors, suggests an updated conceptual model for the pathogenesis of the disorder, and identifies areas for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.